Amgen, Inc. (NASDAQ:AMGN) price target set to $229.00 by Goldman Sachs Group

Analyst Ratings For Amgen, Inc. (NASDAQ:AMGN)

Today, Goldman Sachs Group set its price target on Amgen, Inc. (NASDAQ:AMGN) to $229.00 per share.

There are 12 Hold Ratings, 9 Buy Ratings, no Strong Buy Ratings, no Sell Ratings on the stock.

The current consensus rating on Amgen, Inc. (NASDAQ:AMGN) is Hold with a consensus target price of $204.6195 per share, a potential 4.77% upside.

Some recent analyst ratings include

  • 10/2/2018-Amgen, Inc. (NASDAQ:AMGN) had its Buy rating reiterated by Oppenheimer with a $224.00 price target
  • 10/1/2018-Amgen, Inc. (NASDAQ:AMGN) had its Buy rating reiterated by Cann with a $224.00 price target

Recent Insider Trading Activity For Amgen, Inc. (NASDAQ:AMGN)
Amgen, Inc. (NASDAQ:AMGN) has insider ownership of 0.27% and institutional ownership of 82.48%.

  • On 7/16/2018 Sean E. Harper, EVP, sold 1,525 with an average share price of $195.71 per share and the total transaction amounting to $298,457.75.
  • On 6/12/2018 Sean E. Harper, EVP, sold 1,525 with an average share price of $184.27 per share and the total transaction amounting to $281,011.75.
  • On 5/14/2018 Sean E. Harper, EVP, sold 1,525 with an average share price of $174.10 per share and the total transaction amounting to $265,502.50.
  • On 4/12/2018 Sean E. Harper, EVP, sold 1,525 with an average share price of $172.68 per share and the total transaction amounting to $263,337.00.
  • On 3/16/2018 Sean E. Harper, EVP, sold 1,525 with an average share price of $189.75 per share and the total transaction amounting to $289,368.75.
  • On 2/14/2018 Sean E. Harper, EVP, sold 1,525 with an average share price of $174.18 per share and the total transaction amounting to $265,624.50.
  • On 1/16/2018 Sean E. Harper, EVP, sold 1,525 with an average share price of $185.62 per share and the total transaction amounting to $283,070.50.

About Amgen, Inc. (NASDAQ:AMGN)
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of oncology/hematology, cardiovascular, inflammation, bone health, nephrology, and neuroscience. The company's products include Evenity to treat osteoporosis in postmenopausal women; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Repatha to treat coronary diseases; Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Parsabiv to treat secondary hyperparathyroidism (sHPT); and Aimovig for the prevention of migraine. Its products also comprise Blincyto to treat patients with Philadelphia chromosome-negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia; Kyprolis, a proteasome inhibitor for the treatment of multiple myeloma and small-cell lung cancer; Nplate, a thrombopoietic compound. The company's marketed products include Neulasta, a pegylated protein to treat cancer patients; Aranesp to treat anemia; Sensipar/Mimpara products to treat sHPT in chronic kidney disease; EPOGEN to treat a lower-than-normal number of red blood cells; NEUPOGEN, a recombinant human granulocyte colony-stimulating factor; and IMLYGIC to treat various cancer cells. It serves pharmaceutical wholesale distributors; and physicians or their clinics, dialysis centers, hospitals, and pharmacies, as well as consumers. The company has collaborative agreements with Pfizer Inc.; UCB; Bayer HealthCare Pharmaceuticals Inc.; and The University of Texas MD Anderson Cancer Center. Amgen Inc. was founded in 1980 and is headquartered in Thousand Oaks, California.

Recent Trading Activity for Amgen, Inc. (NASDAQ:AMGN)
Shares of Amgen, Inc. closed the previous trading session at 195.99 up +2.14 1.10% with shares trading hands.

An ad to help with our costs